Sam Chun Dang Pharm. Co., Ltd announced that it expects to receive KRW 20 billion in funding from Korea Investment Partners Co. Ltd.
November 14, 2018
Share
Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:A000250) announced a private placement of series 1 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 and series 2 unregistered coupon unguaranteed private non-detachable bonds for gross proceeds of KRW 10,000,000,000, for aggregate gross proceeds of KRW 20,000,000,000 on November 15, 2018. The transaction will include participation from 2017 KIF-Korea Investment Intelligent Information Fund, Korea Investment Ace Fund (17), Korea Investment Beyond Fund (17), Korea Investment Core Fund 17, Korea Investment Essence Fund(17), Korea Investment Future Fund(17), Korea Investment High Fund(17), Korea Investment Joint Fund(17), Korea Investment Dream Fund(17), funds managed by Korea Investment Partners Co. Ltd. The bonds will be issued at par. The bonds will not carry any coupon and yield to maturity. The bond would mature on November 19, 2021. The convertible bonds will be 100% convertible into 278,940 common shares at a fixed conversion price of KRW 35,850 per share from November 19, 2019 to October 19, 2021. The company will also issue warrants to purchase 278,940 shares at an exercise price of KRW 35,850 for a period starting from November 19, 2019 to October 19, 2021. The subscription date and payment date is November 16, 2018 and November 19, 2018 respectively. The transaction has been approved by the board of directors of the company.
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
SAM CHUN DANG PHARM. CO., LTD 
